Skip to main content
. 2013 Aug 9;23(1):1–11. doi: 10.1093/hmg/ddt387

Figure 6.

Figure 6.

Treatment with selumetinib blocks ERK2 phosphorylation in hearts of LmnaH222P/H222P mice lacking Erk1. (A) Representative immunoblots using antibodies against phosphorylated ERK2, ERK2 and GAPDH to probe proteins extracted from hearts of 20-week-old LmnaH222P/H222P/Erk1−/− mice treated with DMSO placebo or selumetinib. (B) Bar graphs showing quantification of pERK2/ERK2 in hearts 20-week-old LmnaH222P/H222P/Erk1−/− mice treated with DMSO placebo or selumetinib. Values are means ± standard errors (n = 3). *P < 0.05.